NR1H4 and biliary liver cirrhosis: For instance, obeticholic acid (OCA), a potent steroidal FXR agonist, is used in the therapy of ursodeoxycholic acid (UDCA)-resistant primary biliary cholangitis (PBC) and it is additionally investigated for the treatment of other liver diseases such as non-alcoholic steatohepatitis (NASH) (Ðanić et al., 2018; Ratziu et al., 2019).